Probing the Internalization and Efficacy of Antibody‐Drug Conjugate via Site‐Specific Fc‐Glycan Labelling of a Homogeneous Antibody Targeting SSEA‐4 Bearing Tumors

[1]  Young-A. Heo.  Etranacogene Dezaparvovec: First Approval , 2023, Drugs.

[2]  H. Chon,et al.  ez-ADiCon: A novel glyco-remodeling based strategy that enables preparation of homogenous antibody-drug conjugates via one-step enzymatic transglycosylation with payload-preloaded bi-antennary glycan complexes. , 2022, Bioorganic & medicinal chemistry letters.

[3]  Yu Zhang,et al.  Antibody drug conjugate: the “biological missile” for targeted cancer therapy , 2022, Signal Transduction and Targeted Therapy.

[4]  J. Dang,et al.  Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy , 2022, Science advances.

[5]  Joel Morris,et al.  Antibody-Drug Conjugate Targets, Drugs and Linkers. , 2022, Current cancer drug targets.

[6]  F. Albericio,et al.  Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate , 2022, Pharmaceutics.

[7]  Chi‐Huey Wong,et al.  Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer , 2021, Proceedings of the National Academy of Sciences.

[8]  M. Brimble,et al.  An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy , 2021, Molecules.

[9]  Xinbo Zhou,et al.  Antibody–drug conjugates: Recent advances in linker chemistry , 2021, Acta pharmaceutica Sinica. B.

[10]  R. Lerner,et al.  Antibody Libraries as Tools to Discover Functional Antibodies and Receptor Pleiotropism , 2021, International journal of molecular sciences.

[11]  H. Kantarjian,et al.  Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach , 2021, Cancer.

[12]  C. Dumontet,et al.  Antibody–Drug Conjugates: The Last Decade , 2020, Pharmaceuticals.

[13]  Yan Peng,et al.  The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer , 2020, Cancers.

[14]  J. L. Daniotti,et al.  Exploiting the internalization feature of an antibody against the glycosphingolipid SSEA‐4 to deliver immunotoxins in breast cancer cells , 2020, Immunology and cell biology.

[15]  M. Tay,et al.  Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses , 2019, Front. Immunol..

[16]  Massimo Libra,et al.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium , 2018, Front. Pharmacol..

[17]  Jiang Liu,et al.  FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. , 2018, The oncologist.

[18]  Kah Fai Chan,et al.  The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity , 2018, mAbs.

[19]  Lai-Xi Wang,et al.  Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody–drug conjugates , 2017, Nature Protocols.

[20]  Richard A. Lerner,et al.  Combinatorial antibody libraries: new advances, new immunological insights , 2016, Nature Reviews Immunology.

[21]  Marco Thomann,et al.  Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. , 2016, Molecular immunology.

[22]  K. Wittrup,et al.  Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design , 2016, The AAPS Journal.

[23]  Chi‐Huey Wong,et al.  A common glycan structure on immunoglobulin G for enhancement of effector functions , 2015, Proceedings of the National Academy of Sciences.

[24]  P. Burke,et al.  Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index , 2015, Nature Biotechnology.

[25]  C. Bertozzi,et al.  Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development , 2014, Bioconjugate chemistry.

[26]  Peter G Schultz,et al.  Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.

[27]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[28]  R. Lerner,et al.  Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. G. Simmonds,et al.  Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer. , 1983, British Journal of Cancer.